

Contributing to Society through Healthcare



Terumo Blood and Cell Technologies

is a medical technology company founded in 1965. Our products, software and services enable customers to collect and prepare blood and cells to help treat challenging diseases and conditions. Our employees around the world believe in the potential of blood and cells to do even more for patients than they do today.

Blood and cells are the building blocks of health.

Blood delivers **lifesaving therapies**.

Blood therapy **treats diverse pathologies**.

Modified cells may **help cure diseases** or **improve quality of life**.

Treated cells can offer **alternative treatment options** for patients.



Committed to serving more patients

Innovating: Simplifying and automating our customers' operations

Investing: To demonstrate improved health outcomes and expand geographic impact

Collaborating: Across the healthcare ecosystem to serve more patients



Key Facts

Leadership: Antoinette Gawin, President and CEO

Talent: Market-driven employment with 7,000 globally and 2,000 in Colorado

Customers: Located in more than 130 countries with relationships lasting 20 years on average

Locations: Lakewood, Colorado, global headquarters with seven manufacturing sites, six innovation and development centers and five regional headquarters

Focus: Global leader in blood component and therapeutic apheresis

Future: Emerging focus on technologies for source plasma collections, cell and gene therapies and autologous biologics

Terumo Blood and Cell Technologies is part of the **Terumo Group**, which is leveraging comprehensive group strengths across businesses, regions and functions and making healthcare more accessible, wherever in the world we possibly can.

Terumo Group

Founded: 1921

Headquarters: Tokyo, Japan

Employees globally: 25,000+

Capital stock: JPY ¥38.7 billion

Revenue: JPY ¥613.8 billion
(for FYE March 2021)